LA VACUNACIÓN EN LA ENCRUCIJADA

Reflexión crítica sobre la distribución de vacunas para la COVID19 en el mundo

Autores/as

  • Lucas de Candia Universida Nacional de Rosario. Rosario, Santa Fé, Argentina.
  • Jesica Geuna Universidad Nacional de Rosario. Rosario, Santa Fé, Argentina.

DOI:

https://doi.org/10.31052/1853.1180.v27.n1.32772

Palabras clave:

SARS-CoV-2, COVID19, equidad, vacunas, patentes

Resumen

La pandemia por el SARS-CoV-2 azota el mundo. La masiva interconectividad, la transmisión aérea, la contagiosidad presintomática y la ausencia de tratamientos farmacológicos abonaron a su amplia distribución. Los casos se dispararon en todo el mundo. Las herramientas disponibles fueron las intervenciones no farmacológicas clásicas de la epidemiología. Algunos países, las utilizaron eficazmente y lograron controlar la pandemia. El resto atraviesa segundas o terceras olas de casos. La pandemia profundizó previas desigualdades en el mundo. A menos de un año del inicio de la pandemia, la llegada de las vacunas despertó nuevas esperanzas. Sin embargo, la escasez de dosis y las inequidades en su distribución dispararon controversias. El objetivo de la inmunidad de rebaño por vacuna es inalcanzable. Inmunizar a grupos de riesgo para disminuir muertes sólo parece posible en pocos países. Se realizó una reflexión crítica sobre la distribución de las vacunas en el mundo.

Descargas

Los datos de descargas todavía no están disponibles.

Citas

Who.int. 2020 [cited 2022 Jan 12]. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200401-sitrep-72-covid-19.pdf?sfvrsn=3dd8971b_2.

Samet JM, Prather K, Benjamin G, Lakdawala S, Lowe J-M, Reingold A, et al. Airborne transmission of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2): What we know. Clin Infect Dis. 2021;73(10):1924–6.

Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel Coronavirus-infected pneumonia. N Engl J Med. 2020;382(13):1199–207.

Wei WE, Li Z, Chiew CJ. Presymptomatic Transmission of SARS-CoV-2—Singapore, January 23–March 16, 2020. Morbidity and Mortality Weekly Report. 2020;69(14):411.

Lam S, Lombardi A, Ouanounou A. COVID-19: A review of the proposed pharmacological treatments. Eur J Pharmacol. 2020; 886(173451):173451.

Flaxman S, Mishra S, Gandy A, Unwin HJT, Mellan TA, Coupland H, et al. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. Nature. 2020; 584(7820):257–61.

De Candia L, Bulla V, Cordone R, Quignard M, Montaner A, Kohen J. Viejas herramientas para nuevos problemas: Intervenciones no farmacologías para afrontar la pandemia del COVID-19. Rev. argent. salud publica 2021; 13(Suplemento COVID-19): 1-7.

Mortality analyses [Internet]. Johns Hopkins Coronavirus Resource Center. [cited 2022 Jan 12]. Available from: https://coronavirus.jhu.edu/data/mortality.

Heaton PM. The covid-19 vaccine-development multiverse. N Engl J Med. 2020;383(20):1986–8.

Golob JL, Lugogo N, Lauring AS, Lok AS. SARS-CoV-2 vaccines: a triumph of science and collaboration. JCI Insight. 2021 May 10;6(9):e149187.

Bv S. The arrival of Sputnik V. Lancet Infect Dis. 2020;20(10):1128.

Mahase E. Covid-19: What do we know about the late stage vaccine candidates? BMJ. 2020;371:m4576.

Lineamientos técnicos y Manual del vacunador [Internet]. Gob.ar. 2021 [citado el 07 de abril de 2021]. Disponible en: https://www.argentina.gob.ar/coronavirus/vacuna/equipos-salud/lineamientos-manual-vacunador.

Kirby T. New variant of SARS-CoV-2 in UK causes surge of COVID-19. Lancet Respir Med. 2021;9(2):e20–1.

Kirby T. When should the UK lift its lockdown? Lancet Respir Med. 2021;9(4):e44–5.

Kupferschmidt K. Fast-spreading UK virus variant raises alarms. Science. 2021; 9-10.

Wibmer CK, Ayres F, Hermanus T, Madzivhandila M, Kgagudi P, Oosthuysen B, et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med. 2021;27(4):622–5.

Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. N Engl J Med. 2021;384(20):1885–98.

Sabino EC, Buss LF, Carvalho MPS, Prete CA Jr, Crispim MAE, Fraiji NA, et al. Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence. Lancet. 2021;397(10273):452–5.

Singanayagam A, Hakki S, Dunning J, Madon KJ, Crone MA, Koycheva A, et al. Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. Lancet Infect Dis. 2022;22(2):183–95.

Petersen E, Ntoumi F, Hui DS, Abubakar A, Kramer LD, Obiero C, et al. Emergence of new SARS-CoV-2 Variant of Concern Omicron (B.1.1.529) - highlights Africa's research capabilities, but exposes major knowledge gaps, inequities of vaccine distribution, inadequacies in global COVID-19 response and control efforts. Int J Infect Dis. 2022;114:268-272.

Tan SY, Ponstein N. Jonas Salk (1914-1995): A vaccine against polio. Singapore Med J. 2019;60(1):9–10.

Fujimura SF. La vacuna contra la polio, “Gracias Dr. Salk”. Perspectivas de Salud. Organización Panamericana de la Salud. 2005; 10 (2).

Saldías E. Centenario del natalicio del Dr. Albert B Sabin. Rev Chil Infect. 2006;23(4):368–9.

Shampo MA, Kyle RA. Jonas E. Salk discoverer of a vaccine against poliomyelitis. Mayo Clin Proc 1998, 73 (12): 1176.

Tan SY, Ponstein N. Jonas Salk (1914-1995): A vaccine against polio. Singapore Med J. 2019;60(1):9–10.

Ra N, Keusch GT. Salud Mundial: Lecciones de la Ley Bayh-Dole [Internet]. Pipra.org. [cited 2022 Mar 9]. Available from: https://pipra.org/publications-files/F1_8_Nuget.pdf.

Mascola JR, Graham BS, Fauci AS. SARS-CoV-2 viral variants-tackling a moving target. JAMA. 2021;325(13):1261–2.

Goldstein A. Failure to achieve global vaccine equity will have dire consequences. BMJ. 2021;372:n712.

Understanding vaccination progress by country [Internet]. Johns Hopkins Coronavirus Resource Center. [cited 2022 Jan 12]. Available from: https://coronavirus.jhu.edu/vaccines/international.

TÉLAM. Angustia en el mundo por las demoras en la producción y entrega de las vacunas contra el coronavirus [Internet]. Com.ar. [cited 2022 Jan 12]. Available from: https://www.telam.com.ar/notas/202101/542454-angustia-mundo-demora-vacunas-coronavirus.html.

March 8 th -prepared for vaccine supply & production summit COVID-19 vaccine production [Internet]. Ifpma.org. [cited 2022 Jan 12]. Available from: https://www.ifpma.org/wp-content/uploads/2021/03/Airfinity_global_summit_master_final.pdf

Mathieu E, Ritchie H, Ortiz-Ospina E, Roser M, Hasell J, Appel C, et al. A global database of COVID-19 vaccinations. Nat Hum Behav. 2021;5(7):947–53.

La OMS critica el egoísmo de los países ricos y las farmacéuticas frente a las vacunas del COVID-19 [Internet]. Noticias ONU. 2021 [cited 2022 Jan 12]. Available from: https://news.un.org/es/story/2021/01/1486742.

Goldstein A. Failure to achieve global vaccine equity will have dire consequences. BMJ. 2021;372:n712.

Mathieu E, Ritchie H, Ortiz-Ospina E, Roser M, Hasell J, Appel C, et al. A global database of COVID-19 vaccinations. Nat Hum Behav. 2021;5(7):947–53.

Barda N, Dagan N, Cohen C, Hernán MA, Lipsitch M, Kohane IS, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021;398(10316):2093–100.

Burki TK. Fourth dose of COVID-19 vaccines in Israel. Lancet Respir Med. 2022;10(2):e19.

Minsal.cl. [cited 2022 jan 12]. Available from: https://www.minsal.cl/covid-19-gobierno-anuncia-que-este-proximo-lunes-comienza-el-proceso-de-vacunacion-de-cuarta-dosis/.

Alocución de apertura del Director General de la OMS en la rueda de prensa sobre la COVID-19 del 6 de enero de 2022 [Internet]. Who.int. [cited 2022 Jan 12]. Available from: https://www.who.int/es/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---6-january-2022.

COVAX: colaboración para un acceso equitativo mundial a las vacunas contra la COVID-19 [Internet]. Who.int. [cited 2022 Jan 12]. Available from: https://www.who.int/es/initiatives/act-accelerator/covax.

McAdams D, McDade KK, Ogbuoji O, Johnson M, Dixit S, Yamey G. Incentivising wealthy nations to participate in the COVID-19 Vaccine Global Access Facility (COVAX): a game theory perspective. BMJ Glob Health. 2020;5(11):e003627.

Nytimes.com. [cited 2022 Jan 12]. Available from: https://www.nytimes.com/2021/01/12/opinion/world-covid-vaccines.html.

COVAX informa a los participantes de los retrasos en la ‎entrega de vacunas del Serum institute de la India (sii) y ‎AstraZeneca [Internet]. Who.int. [cited 2022 Jan 12]. Available from: https://www.who.int/es/news/item/25-03-2021-covax-updates-participants-on-delivery-delays-for-vaccines-from-serum-institute-of-india-(sii)-and-astrazeneca.

Usher AD. “A beautiful idea: how COVAX has fallen short.” Lancet (London, England) vol. 397,10292 (2021): 2322-2325.

Amanat F, Krammer F. SARS-CoV-2 Vaccines: Status Report. Immunity. 2020 Apr 14;52(4):583-589.

Edridge A, Kaczorowska J, Hoste A, Bakker M, Klein M, Loens, K, et al. Seasonal coronavirus protective immunity is short-lasting. Nature medicine 2021, 26(11): 1691–93.

BOLETIN OFICIAL REPUBLICA ARGENTINA - MEDIDAS GENERALES DE PREVENCIÓN - Decisión Administrativa 1198/2021 [Internet]. Gob.ar. [cited 2022 Jan 19]. Available from: https://www.boletinoficial.gob.ar/detalleAviso/primera/254239/20211213.

Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671–81.

Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15.

Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111.

Mallapaty S. Can COVID vaccines stop transmission? Scientists race to find answers. Nature. 2021. doi: 10.1038/d41586-021-00450-z. Epub ahead of print.

Tiyo BT, Schmitz GJH, Ortega MM, da Silva LT, de Almeida A, Oshiro TM, et al. What happens to the immune system after vaccination or recovery from COVID-19? Life (Basel). 2021;11(11):1152.

Dejnirattisai W, Huo J, Zhou D, Zahradník J, Supasa P, Liu C, et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell. 2022;185(3):467-484.e15.

De Candia LF, Santucci N, Alloatti A, Barchiesi J, Bergonzi M, Blázquez F, et al. Efecto de la vacunación sobre la transmisión intradomiciliaria del SARS-COV-2, provincia de Santa Fe, Argentina, 2021. Rev. argent. salud publica 2021; 13(Suplemento COVID-19): 1-6.

Fernández L, Shorett P. Lessons in equity from the front lines of COVID-19 vaccination. JAMA Health Forum. 2021;2(4):e210612.

Barsky BA, Reinhart E, Farmer P, Keshavjee S. Vaccination plus decarceration - stopping covid-19 in jails and prisons. N Engl J Med. 2021;384(17):1583–5.

Quinn SC, Andrasik MP. Addressing Vaccine Hesitancy in BIPOC Communities - Toward Trustworthiness, Partnership, and Reciprocity. N Engl J Med. 2021;385(2):97.

Mathieu E, Ritchie H, Ortiz-Ospina E, et al. A global database of COVID-19 vaccinations [published correction appears in Nat Hum Behav. 2021 Jun 17]. Nat Hum Behav. 2021;5(7):947-953.

Hotez P. COVID vaccines: time to confront anti-vax aggression. Nature. 2021; 592, 661.

Los líderes mundiales piden un nuevo tratado internacional para mejorar la respuesta a una pandemia [Internet]. Noticias ONU. 2021 [cited 2022 Jan 12]. Available from: https://news.un.org/es/story/2021/03/1490312.

La APDH solicitó con urgencia a Naciones Unidas que se liberen las patentes de las vacunas por el COVID 19 [Internet]. APDH. [cited 2022 Jan 12]. Available from: https://apdh.org.ar/declaraciones/onu-liberen-patentes-vacunas.

Katz IT, Weintraub R, Bekker LG, Brandt AM. From Vaccine Nationalism to Vaccine Equity - Finding a Path Forward. N Engl J Med. 2021;384(14):1281-1283.

Publicado

2022-08-12

Cómo citar

1.
de Candia L, Geuna J. LA VACUNACIÓN EN LA ENCRUCIJADA: Reflexión crítica sobre la distribución de vacunas para la COVID19 en el mundo. Rev. Salud Pública (Córdoba) [Internet]. 12 de agosto de 2022 [citado 28 de marzo de 2024];27(1). Disponible en: https://revistas.unc.edu.ar/index.php/RSD/article/view/32772

Número

Sección

Artículos Originales